Reed Jobs, the son of Apple founder Steve Jobs, has taken a deeply personal tragedy and turned it into a mission to fight against cancer. At the age of 12, Reed’s father was diagnosed with pancreatic cancer, a disease that ultimately took his life at the young age of 56. This devastating loss inspired Reed to dedicate his career to investing in companies focused on preventing cancer-related deaths.
With a vision of transforming cancer from a death sentence to a chronic, manageable disease, Reed founded Yosemite, a venture capital firm named after the national park where his parents were married. Initially a part of the Emerson Collective, a philanthropic organization founded by his mother, Laurene Powell Jobs, Reed spun out Yosemite in 2023 with an initial fund of $263 million. The firm has since invested in approximately 20 companies, including gene therapy firm Tune Therapeutics and AI drug development startup Chai Discovery.
Yosemite recently announced the successful raising of over $200 million for their second fund, with a targeted size of $350 million. Notable investors in this fund include biotech giant Amgen, Memorial Sloan Kettering, MIT, and venture capitalist John Doerr. Reed Jobs, as a general partner, is also personally invested in the fund along with his mother through Emerson Collective.
The focus of Yosemite’s investments spans across various types of cancers, from more treatable forms like colon cancer to more aggressive and deadly types like pancreatic cancer. Reed Jobs emphasizes the importance of early detection, targeted therapies, and continuous monitoring in driving down cancer mortality rates.
Despite managing over $1 billion in assets, Yosemite is considered a smaller player in the venture capital world. However, Reed’s unique motivation and personal connection to the cause have made the firm a significant player in the healthcare and oncology space. Reed’s approach combines traditional VC investments with no-strings-attached grants to scientists, bridging the gap between scientific discoveries and commercialization.
One of the companies that benefited from Yosemite’s early-stage grants is Azalea Therapeutics, a gene therapy company focused on in vivo treatments. Another notable investment is Chai Discovery, a startup using AI to design proteins for new drugs, with a recent partnership with Eli Lilly to develop innovative medicines.
Reed Jobs’ journey from tragedy to transformation showcases his unwavering commitment to making a difference in the fight against cancer. Through Yosemite, he continues to drive innovation and progress in the field of oncology, with a vision of turning cancer into a manageable chronic disease in the near future. Reed Jobs, the founder of Yosemite, believes that Chai Discovery is poised to become one of the most significant companies of this decade. With a focus on cutting-edge scientific breakthroughs in cancer treatment, Chai Discovery is at the forefront of a rapidly evolving industry. Jobs emphasizes the importance of supporting researchers and advancing the state of science in America.
The landscape of cancer treatment has drastically changed over the past 15 years, with companies like Merck leading the way with their blockbuster drug Keytruda. This early immunotherapy has revolutionized the treatment of lung cancer and melanoma, generating $30 billion in annual sales. Additionally, advanced treatments like CAR-T cell therapy are paving the way for personalized immunotherapy that harnesses the power of a person’s immune system to combat cancer.
Yosemite’s new fund, which has garnered investment from companies like Amgen, is set to support groundbreaking science in its earliest stages. With a focus on investing in approximately 25 companies, Jobs envisions a future where radiopharmaceuticals and AI-driven healthcare solutions play a vital role in cancer treatment. Gene therapy is also a key area of focus for Chai Discovery, with Jobs highlighting the potential for a new class of therapies to emerge.
In addition to gene therapy, Jobs sees tremendous potential in cancer vaccines as a means of preventing and treating cancer at its core. By jumpstarting the immune system of individuals at risk of developing cancer, vaccines could offer a new frontier in cancer treatment. Jobs is committed to supporting research in this area, advocating for continued investment in mRNA research to drive progress in cancer vaccine development.
As Chai Discovery continues to forge ahead in the field of cancer treatment, Jobs remains optimistic about the future of the industry. By investing in cutting-edge technologies and supporting innovative research, Chai Discovery is well-positioned to make a significant impact on the fight against cancer.
